Stock Events

Stock Events

Cns Pharmaceuticals 

$2.7
74
+$0.06+2.27% Today

Statistics

Day High
2.65
Day Low
2.41
52W High
16.32
52W Low
2.13
Volume
19,733
Avg. Volume
49,418
Mkt Cap
1.67M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-24
-17.67
-11.33
-5
Expected EPS
-5.37
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-29.72MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CNSP. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap5.56B
Alkermes plc works on central nervous system (CNS) diseases, offering products that could be in direct competition with CNSP's pipeline.
Biogen
BIIB
Mkt Cap25.38B
Biogen Inc. has a broad portfolio of treatments for neurological and neurodegenerative diseases, competing in the CNS space.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.71B
ACADIA Pharmaceuticals focuses on the development and commercialization of medicines to treat central nervous system disorders, directly competing with CNSP.
AMGEN
AMGN
Mkt Cap189.22B
Amgen Inc. has a diverse biopharmaceutical portfolio, including treatments for neurological disorders, making it a competitor in the CNS market.
Novartis
NVS
Mkt Cap297.35B
Novartis AG offers a wide range of healthcare solutions, including treatments for CNS disorders, competing with CNSP's therapeutic areas.
Pfizer
PFE
Mkt Cap153.13B
Pfizer Inc. has a significant presence in the development of drugs for neurological conditions, making it a competitor in the CNS pharmaceuticals market.
Merck
MRK
Mkt Cap300.2B
Merck & Co., Inc. develops therapies for various diseases, including CNS disorders, positioning it as a competitor to CNSP.
Johnson & Johnson
JNJ
Mkt Cap574.66B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments for CNS disorders, competing with CNSP in the broader healthcare market.

About

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Show more...
CEO
Mr. Christopher S. Downs CPA, CTP, FP&A
Employees
4
Country
United States
ISIN
US18978H5081

Listings

F
DE
BE50.F
STU
DE
ZA6.STU
XNAS
US
CNSP
OTC Link
US
MNMRF

0 Comments

Share your thoughts

FAQ

What is Cns Pharmaceuticals stock price today?▼
The current price of CNSP is $2.7 USD — it has increased by +2.27% in the past 24 hours. Watch Cns Pharmaceuticals stock price performance more closely on the chart.
What is Cns Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cns Pharmaceuticals stocks are traded under the ticker CNSP.
Is Cns Pharmaceuticals stock price growing?▼
CNSP stock has risen by +23.85% compared to the previous week, the month change is a +10.66% rise, over the last year Cns Pharmaceuticals has showed a -76.49% decrease.
What is Cns Pharmaceuticals market cap?▼
Today Cns Pharmaceuticals has the market capitalization of 1.67M
When is the next Cns Pharmaceuticals earnings date?▼
Cns Pharmaceuticals is going to release the next earnings report on May 18, 2026.
What were Cns Pharmaceuticals earnings last quarter?▼
CNSP earnings for the last quarter are -5.09 USD per share, whereas the estimation was -5.09 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cns Pharmaceuticals revenue for the last year?▼
Cns Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Cns Pharmaceuticals net income for the last year?▼
CNSP net income for the last year is -29.72M USD.
How many employees does Cns Pharmaceuticals have?▼
As of April 15, 2026, the company has 4 employees.
In which sector is Cns Pharmaceuticals located?▼
Cns Pharmaceuticals operates in the Health & Wellness sector.
When did Cns Pharmaceuticals complete a stock split?▼
The last stock split for Cns Pharmaceuticals was on July 22, 2025 with a ratio of 1:12.
Where is Cns Pharmaceuticals headquartered?▼
Cns Pharmaceuticals is headquartered in Houston, United States.